"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 4 | 2 | 6 |
| 2007 | 3 | 2 | 5 |
| 2008 | 6 | 3 | 9 |
| 2009 | 5 | 2 | 7 |
| 2010 | 4 | 5 | 9 |
| 2011 | 2 | 2 | 4 |
| 2012 | 3 | 1 | 4 |
| 2013 | 2 | 3 | 5 |
| 2014 | 7 | 3 | 10 |
| 2015 | 7 | 3 | 10 |
| 2016 | 3 | 4 | 7 |
| 2017 | 5 | 3 | 8 |
| 2018 | 7 | 3 | 10 |
| 2019 | 5 | 5 | 10 |
| 2020 | 2 | 3 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 5 | 5 |
| 2024 | 4 | 1 | 5 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. Ann Intern Med. 2026 Jul; 179(7):917-928.
-
Evidence-Based Positioning of Sodium-Glucose Co-transporter?2 Inhibitors and Glucagon-Like Peptide?1 Receptor Agonists in the Management of Chronic Kidney Disease with Type?2 Diabetes and Overweight or Obesity: A Systematic Literature Review. Adv Ther. 2026 May; 43(5):1983-2000.
-
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
-
Glycaemic treatment of newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2024 Nov; 26(11):5492-5493.
-
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816.
-
Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians. Diabetes Obes Metab. 2024 Aug; 26(8):3475-3477.
-
Edible wild plants, chicory and purslane, alleviated diabetic testicular dysfunction, and insulin resistance via suppression 8OHdg and oxidative stress in rats. PLoS One. 2024; 19(4):e0301454.
-
Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
-
In adults with BMI =27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk. Ann Intern Med. 2023 11; 176(11):JC129.
-
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 08 05; 402(10400):472-483.